ASTRO 2026 Annual Meeting
Trials whose public commentary places their results at ASTRO 2026 Annual Meeting, Sep 26–30, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
6 trials: 0 with reports and 6 with no report yet. Organised by American Society for Radiation Oncology (ASTRO); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
No published report on a trial placed at ASTRO 2026 Annual Meeting yet.
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma · 1 | |||||||
| NRG-GI003 Tests a strategy, not a drug placed at ASTRO 2026 Annual Meeting by 7 sources NCT03186898 · NRG Oncology DeepView → | unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||
| Non-small cell lung cancer · 1 | |||||||
| MDT-BRIDGE durvalumab plus platinum-based chemotherapy placed at ASTRO 2026 Annual Meeting by 3 sources NCT05925530 · AstraZeneca DeepView → | resectable or borderline resectable stage IIB–IIIB NSCLC | Phase 2 | Deep | View | |||
| Prostate cancer · 3 | |||||||
| PACE Drug not named yet placed at ASTRO 2026 Annual Meeting by 14 sources NCT01584258 · Royal Marsden NHS Foundation Trust DeepView → | organ-confined prostate cancer | Phase 3 | Deep | View | |||
| NRG-GU006 apalutamide placed at ASTRO 2026 Annual Meeting by 2 sources NCT03371719 · NRG Oncology DeepView → | recurrent prostate cancer | Phase 2 | Deep | View | |||
| POTEN-C Tests a strategy, not a drug placed at ASTRO 2026 Annual Meeting by 2 sources NCT03525262 · University of Texas Southwestern Medical Center StandardView → | localized prostate cancer | Phase 2 | Standard | View | |||
| Small cell lung cancer · 1 | |||||||
| MAVERICK Tests a strategy, not a drug placed at ASTRO 2026 Annual Meeting by 5 sources NCT04155034 · SWOG Cancer Research Network DeepView → | small cell lung cancer | Phase 3 | Deep | View | |||